Background-Impacts of a single radiofrequency ablation (RFA) on quality of life (QoL) were not well investigated in atrial fibrillation (AF) patients with low stroke risk. Methods and Results-Nine hundred AF patients with low CHADS(2) score (ie, CHADS(2) <= 1) who completed both a baseline and 6-month Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire were selected from The Chinese Atrial Fibrillation Registry between 2011 and 2013. A final cohort of 222 patients was constructed after a propensity score matching with 74 in the RFA group and 148 in the non-RFA group. Domains of AFEQT were balanced at baseline between the 2 groups. No statistically significant differences were noted in QoL (all P>0.05) when AFEQT at 6 months was compared between groups, except for the symptoms domain (83.07 +/- 12.37 units in the RFA group vs. 77.68 +/- 17.14 units in the non-RFA group; P=0.008) and treatment satisfaction domain (76.34 +/- 14.92 units in the RFA group vs. 70.38 +/- 16.81 units in the non-RFA group; P=0.01). Within-group changes in all domains and the global score of the questionnaire were moderate to large, whereas between-group comparisons in baseline to 6-month changes and QoL at 6 months were small to moderate according to Cohen effect sizes. Conclusions-QoL was balanced at baseline and improved at 6 months in both groups from this observational propensity-matched cohort based on the AFEQT questionnaire. However, RFA treatment was only associated with small-to-moderate superiorities over non-RFA treatment. The role of RFA in QoL improvement among AF patients with low stroke risk requires further research.
基金：
grants (2013BAI09B02 and
2013DFB30310) from the Ministry of Science and Technology
of the People’s Republic of China and grants (D11110000
3011004 and D131100002313001) from Beijing Municipal
Commission of Science and Technology and Beijing Municipal
Administration of Hospitals Clinical Medicine Development of
Special Funding Support (code: ZYLX201302). The construction of CAFR was also granted by Bristol-Myers Squibb (BMS),
Pfizer, Johnson & Johnson, Boehringer Ingelheim (BI), and
Bayer.
第一作者机构：[1]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, Beijing 100029, Peoples R China
通讯作者：
通讯机构：[1]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, Beijing 100029, Peoples R China[*1]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, 2 Anzhen Rd, Beijing 100029, Peoples R China
推荐引用方式(GB/T 7714)：
Bai Ying,Bai Rong,Wu Jia-Hui,et al.Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation[J].JOURNAL OF THE AMERICAN HEART ASSOCIATION.2015,4(9):doi:10.1161/JAHA.115.002130.
APA：
Bai, Ying,Bai, Rong,Wu, Jia-Hui,Zhang, Ting,Liu, Nian...&Ma, Chang-Sheng.(2015).Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation.JOURNAL OF THE AMERICAN HEART ASSOCIATION,4,(9)
MLA：
Bai, Ying,et al."Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation".JOURNAL OF THE AMERICAN HEART ASSOCIATION 4..9(2015)
医学